Visugromab, nivolumab and lenvatinib compared to double placebo and lenvatinib in unresectable or metastatic hepatocellular carcinoma post anti-PD-(L)1 failure

Authors
Category Primary study
Registry of TrialsClinical Trials Information System
Year 2025
This article has no abstract
Epistemonikos ID: 3d1df98e24d65f3a508134684a661345d36a1a33
First added on: Jan 17, 2026